Sebastian Mejia, Nikia Stewart, Angel Miller, Roman Savicky, Christopher Monarski, George E Moore, Dennis Keith
{"title":"Accuracy of external measurements of 3-dimensional (3D) printed biomodels of the canine radius used in an in-hospital setting.","authors":"Sebastian Mejia, Nikia Stewart, Angel Miller, Roman Savicky, Christopher Monarski, George E Moore, Dennis Keith","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The objective of this study was to determine if biomodels printed on a fused deposition modeling (FDM) device from computed tomography (CT) data are accurate by comparing external measurements to the native bone, considering that the clinical usefulness of the printed biomodels in an in-hospital setting depends on their verified accuracy and consistency. Using canine cadaveric radii previously stripped of all soft tissues, 7 parameters of the actual bone and the 3-dimensional (3D) printed biomodels were measured and compared to determine how accurately the models represent the cadaveric bone. A total of 28 canine radii were collected, in which the landmarks for measurements were established. Radiographs were then taken to determine the frontal center of rotation of angulation (CORA) and CT scans were carried out. Finally, a 3D virtual reconstruction was done and converted into a stereolithography (STL) format file, from which 2 biomodels were printed per bone. Measurements for biomodels were compared for equivalence to cadaveric measurements. For the 7 measured parameters, the mean difference between biomodel and cadaveric parameters ranged from an increase of +0.66% in cranial-caudal proximal (CrCdP)-CORA to a decrease of -1.32% in distal width of the radius. For all 7 measured parameters, measurements for biomodels were statistically equivalent to their corresponding cadaveric bone (<i>P</i> < 0.001). The 7 measured parameters in the 3D models printed with an FDM device were not significantly different than those in the original bone. In fact, these measurements closely approximated original bone measurements (within 1.5%); therefore, validating their application in future presurgical planning for various orthopedic procedures.</p>","PeriodicalId":93919,"journal":{"name":"Canadian journal of veterinary research = Revue canadienne de recherche veterinaire","volume":"83 3","pages":"181-186"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587886/pdf/cjvr_03_181.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41223557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A missense mutation in MYO7A is associated with bilateral deafness and vestibular dysfunction in the Doberman pinscher breed.","authors":"Aubrey A Webb, Alison L Ruhe, Mark W Neff","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Bilateral deafness with concurrent vestibular dysfunction was first reported in the Doberman pinscher in 1980. Here, we identify a coding mutation in the MYO7A gene that is perfectly associated with the disorder. The lack of visual deficits in affected dogs suggests that, like rodents but unlike humans, MYO7A is not required for retinal function. DNA testing of the mutation will enable dog breeders to manage the incidence of this genetic defect.</p>","PeriodicalId":93919,"journal":{"name":"Canadian journal of veterinary research = Revue canadienne de recherche veterinaire","volume":"83 2","pages":"142-148"},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450158/pdf/cjvr_02_142.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41124193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jonathan A Lidbury, Aline Rodrigues Hoffmann, Joanna K Fry, Jan S Suchodolski, Jörg M Steiner
{"title":"Evaluation of hyaluronic acid, procollagen type III N-terminal peptide, and tissue inhibitor of matrix metalloproteinase-1 as serum markers of canine hepatic fibrosis.","authors":"Jonathan A Lidbury, Aline Rodrigues Hoffmann, Joanna K Fry, Jan S Suchodolski, Jörg M Steiner","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The only way to diagnose hepatic fibrosis in dogs is by histological assessment of a liver biopsy specimen. As this technique is invasive and susceptible to sampling variation, serum biomarkers are used to detect hepatic fibrosis in humans. The objective of this study was to assess the utility of hyaluronic acid (HA), procollagen type III N-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) as serum markers of canine hepatic fibrosis. Serum samples were collected from 47 dogs with histologically confirmed hepatobiliary disease and 24 healthy dogs in order to measure concentrations of HA, PIIINP, and TIMP-1. Hepatic fibrosis was staged using a 5-point scoring scheme. There was no correlation between serum concentrations of HA or PIIINP and the severity of hepatic fibrosis. There was a negative correlation between serum concentration of TIMP-1 and the severity of hepatic fibrosis (<i>r</i><i><sub>s</sub></i> = -0.33; <i>P</i> = 0.036). It was not possible to use serum concentrations of HA, PIIINP, or TIMP-1 to discriminate between dogs with absent-to-moderate hepatic fibrosis and those with marked-to-very-marked fibrosis. The results of this study do not support the utility of measuring serum concentrations of HA, PIIINP, or TIMP-1 for diagnosing canine hepatic fibrosis. Further studies are needed to support this finding.</p>","PeriodicalId":93919,"journal":{"name":"Canadian journal of veterinary research = Revue canadienne de recherche veterinaire","volume":"80 4","pages":"302-308"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141181672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lígia F Gundim, Camila P de Araújo, William T Blanca, Ednaldo C Guimarães, Alessandra A Medeiros
{"title":"Clinical staging in bitches with mammary tumors: Influence of type and histological grade.","authors":"Lígia F Gundim, Camila P de Araújo, William T Blanca, Ednaldo C Guimarães, Alessandra A Medeiros","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Breast tumors are the most common tumors in dogs and the study of disease prognostic factors is important for establishing the appropriate treatment protocols. The purpose of this study was to clinically stage mammary tumors of bitches and correlate the stages with histological type and grade. The tumors of 63 dogs were clinically staged based on the findings of tumor sizing, lymph node evaluation, and radiographic examination. After surgical excision, the tumors were classified histologically and graded. The relationship between the tumor grade, stage, and histological type was evaluated using a binomial test. Stage I tumors were the most numerous (31.75%), followed by tumors at stages II, III, IV, and V. Animals with histological grade I carcinomas presented stage I, II, or III tumors more frequently and stage IV and V tumors less frequently. The number of animals with simple carcinomas that were at stage I of the disease was greater than that at stage V. Carcinomas in the mixed tumors were less aggressive; however, the small number of animals in stage V of the disease made any statistical association impossible. The complex carcinomas presented with the invasion of the lymph nodes and less cellular differentiation in a larger number of animals than did simple carcinomas. Histological grading proved to be the best parameter for the prognostic evaluation of the breast carcinomas.</p>","PeriodicalId":93919,"journal":{"name":"Canadian journal of veterinary research = Revue canadienne de recherche veterinaire","volume":"80 4","pages":"318-322"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140289891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor.","authors":"Masaya Igase, Chung Chew Hwang, Satoshi Kambayashi, Masato Kubo, Matt Coffey, Takako Shimokawa Miyama, Kenji Baba, Masaru Okuda, Shunsuke Noguchi, Takuya Mizuno","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The oncolytic effects of reovirus in various cancers have been proven in many clinical trials in human medicine. Oncolytic virotherapy using reovirus for canine cancers is being developed in our laboratory. The objective of this study was to examine the synergistic anti-cancer effects of a combination of reovirus and low doses of various chemotherapeutic agents on mammary gland tumors (MGTs) in dogs. The first part of this study demonstrated the efficacy of reovirus in canine MGTs in vitro and in vivo. Reovirus alone exerted significant cell death by means of caspase-dependent apoptosis in canine MGT cell lines. A single injection of reovirus impeded growth of canine MGT tumors in xenografted mice, but was insufficient to induce complete tumor regression. The second part of this study highlighted the anti-tumor effects of reovirus in combination with low doses of paclitaxel, carboplatin, gemcitabine, or toceranib. Enhanced synergistic activity was observed in the MGT cell line treated concomitantly with reovirus and in all the chemotherapeutic agents except toceranib. In addition, combining reovirus with paclitaxel or gemcitabine at half dosage of half maximal inhibitory concentration (IC50) enhanced cytotoxicity by activating caspase 3. Our data suggest that the combination of reovirus and low dose chemotherapeutic agents provides an attractive option in canine cancer therapy. </p>","PeriodicalId":93919,"journal":{"name":"Canadian journal of veterinary research = Revue canadienne de recherche veterinaire","volume":"80 1","pages":"21-31"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}